Therapeutic Response

EGFR p.L858R status confers therapeutic sensitivity to Amivantamab in combination with Lazertinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Rybrevant (amivantamab-vmjw) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
Rybrevant (amivantamab) [product information]. EMA. The European Medicines Agency (EMA) has authorized amivantamab in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).
Rybrevant (amivantamab) [product information]. EMA. The European Medicines Agency (EMA) has authorized amivantamab in combination with lazertinib for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations.
Lazcluze (lazertinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to lazertinib in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
Lazcluze (lazertinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized lazertinib in combination with amivantamab is indicated for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations.